What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) — derived from a protective protein found naturally in human gastric juice. Its molecular weight is 1419.56 Da (ChEMBL: CHEMBL4297358; DrugBank: DB11882; CAS: 137525-51-0).

Unlike most peptides, BPC-157 demonstrates remarkable stability against enzymatic degradation and gastric acid, which has made it a candidate for both injectable and oral administration routes. A Phase I clinical trial (NCT02637284) evaluated oral tablets in healthy volunteers, while a Phase II trial (NCT07437547) is currently recruiting for subcutaneous injection in hamstring injuries.

Mechanism of Action

BPC-157’s therapeutic effects are mediated through two convergent angiogenic pathways, both of which increase nitric oxide (NO) production:

VEGF-dependent pathway: BPC-157 enhances expression and endocytosis of VEGFR2 (vascular endothelial growth factor receptor 2), triggering the PI3K → Akt → eNOS cascade. This promotes new blood vessel formation and delivers oxygen and nutrients to damaged tissue.

VEGF-independent pathway: BPC-157 also activates Src kinase → Caveolin-1 phosphorylation → eNOS activation, providing an alternative route to NO production that operates even when VEGF signaling is impaired.

Beyond angiogenesis, BPC-157 activates:

• ERK1/2 signaling — cell proliferation and differentiation
• FAK/paxillin — cell adhesion, migration, and wound closure
• Heme oxygenase-1 (HO-1) — cytoprotection against oxidative stress
• Heat shock proteins — cellular stress response and protein homeostasis
• Growth hormone receptor — enhanced tissue regeneration signaling

This multi-pathway convergence explains why BPC-157 shows effects across diverse tissue types — musculoskeletal, gastrointestinal, neurological, and vascular — rather than being limited to a single organ system.

Clinical Evidence

Human Studies

Human clinical data for BPC-157 remains limited but growing:

• Chronic knee pain (clinical study): 7 of 12 patients reported pain relief lasting over six months after a single BPC-157 injection.
• IV safety pilot (2025, PMID: 40131143): Two healthy adults received intravenous BPC-157 infusions up to 20 mg with no adverse events and no clinically meaningful changes in vital signs, ECGs, or laboratory biomarkers.
• Phase I (NCT02637284): Oral tablets (1–6 mg) evaluated in 42 healthy volunteers for safety and pharmacokinetics.
• Phase II (NCT07437547, recruiting 2026): 120 patients with acute Grade II hamstring strain receiving subcutaneous injection daily for 14 days, with MRI-assessed tissue healing as primary endpoint.

Preclinical Evidence

A 2025 systematic review (Vasireddi et al., PMID: 40756949) analyzed 36 studies — 35 preclinical and 1 clinical — on BPC-157 in orthopedic sports medicine. Preclinical results consistently demonstrate:

• Accelerated healing of tendon ruptures, ligament tears, and muscle injuries
• Enhanced bone fracture repair
• Counteraction of NSAID-induced gastrointestinal damage (Seiwerth et al., PMID: 22950504)
• Neuroprotective effects via brain-gut axis modulation (Sikiric et al., PMID: 28829746)

Molecular Properties & Bioavailability

Property	Value	Significance
Molecular Weight	1419.56 Da	Far exceeds Lipinski’s 500 Da cutoff
XLogP	-9	Extremely hydrophilic — poor membrane permeability
TPSA	573 Ų	>140 Ų indicates poor oral absorption
H-bond Donors	16	Lipinski limit: ≤5
H-bond Acceptors	24	Lipinski limit: ≤10
Rotatable Bonds	39	High conformational flexibility

BPC-157 fails all five Lipinski Rule of Five criteria, which typically predicts poor oral bioavailability for most peptides. However, its unusual stability against proteolytic degradation (attributed to the proline-rich N-terminal region) has led researchers to investigate oral delivery — the Phase I trial used oral tablets, suggesting at least partial gastrointestinal absorption.

Administration routes studied: Subcutaneous injection (most common), intramuscular injection, intravenous infusion, oral tablets, intraperitoneal (preclinical).

Drug Interactions & Contraindications

BPC-157’s interaction profile is primarily characterized through its effects on adrenergic and dopaminergic systems:

Known interactions (from preclinical studies):

• Alpha-adrenergic blockers (phentolamine): Abolishes BPC-157’s gastroprotective effect
• Alpha-2 agonists (clonidine): Abolishes gastroprotective effect
• Dopamine antagonists (haloperidol): Abolishes gastroprotective effect
• Beta-blockers: Route-dependent — atenolol blocks IP administration effects; propranolol blocks intragastric effects
• NSAIDs: BPC-157 may counteract NSAID-induced gastrointestinal damage — potential for therapeutic synergy but also reduced NSAID efficacy at the gut level

Not affected by: Prazosin, yohimbine, domperidone

Populations with unknown risk: Pregnancy, pediatric, renal/hepatic impairment — no human data exists for these populations.

Safety & Side Effects

No adverse effects have been reported in published preclinical studies. The 2025 IV safety pilot (PMID: 40131143) in 2 healthy adults showed no clinical concerns up to 20 mg.

However, anonymous user reports from unregulated sources describe: injection site pain and swelling, anxiety, heart palpitations, insomnia, drowsiness, fatigue, depression, and anhedonia. These may relate to BPC-157’s dopaminergic and serotonergic pathway modulation, or to contamination in non-pharmaceutical-grade products.

Critical limitation: No long-term human safety data exists. BPC-157 is not FDA-approved and is banned by WADA/USADA in professional sports.